Collaboration between Gene2Cure Foundation and Viralgen
The Gene2Cure Foundation, a non-profit organization focused on promoting the development and clinical translation of innovative gene therapies for pediatric rare and ultra-rare genetic disorders, announced a collaboration with Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) based gene therapies.
This partnership aims to enhance the production and advancement of a portfolio of investigational gene therapy programs intended to address rare genetic conditions that currently lack effective treatments. The agreement allows Gene2Cure to leverage Viralgen's proprietary Aava™ manufacturing platform to accelerate the clinical phase of their gene therapy initiatives targeting specific conditions, including PUS3 syndrome, Smith-Lemli-Opitz syndrome, and GAND.
Viralgen's role will involve providing customized AAV manufacturing services tailored to the unique requirements of each program, whether it be for toxicology studies or for clinical use. The Aava™ platform is engineered to provide a scalable manufacturing route applicable to various AAV serotypes, thus facilitating the transition of programs from preclinical to clinical development and eventual commercialization.
Professor Leszek Lisowski, co-founder and president of the Gene2Cure Foundation, expressed his enthusiasm for the collaboration, stating, "We are excited to work with Viralgen to bring experimental gene therapies closer to children suffering from incurable genetic conditions. By helping us develop therapies more quickly and cost-effectively, this partnership offers hope to affected children and their families."
Jimmy Vanhove, CEO of Viralgen, remarked on the significance of such collaborations for advancing potential gene therapies for rare diseases. He stated, "This partnership is critical in pushing forward gene therapies for rare diseases, especially where development pathways can be complex. We are thrilled to support Gene2Cure in advancing their programs through key stages of preclinical and clinical development, enabling access to our Aava™ manufacturing platform."
About Gene2Cure Foundation
Gene2Cure Foundation is a 501(c)(3) non-profit organization based in the United States, dedicated to advancing potentially life-saving gene therapies for children affected by rare and ultra-rare genetic disorders. With a global outreach, the foundation combines expertise in scientific research, clinical applications, and manufacturing to transform promising research into experimental treatments for conditions with few or no therapeutic options. Supported by philanthropic donations, Gene2Cure focuses on developing safe and effective therapies as quickly and cost-efficiently as possible, ensuring that every contribution improves the lives of affected children and their families. For more information, visit
gene2cure.com and follow Gene2Cure on LinkedIn, Instagram, Facebook, and YouTube.
About Viralgen
Viralgen is a leading contract development and manufacturing organization focused exclusively on AAV-based gene therapies. Founded in 2017 as a subsidiary of AskBio Inc., within the Bayer AG group, Viralgen provides comprehensive support, ranging from initial development stages to large-scale commercial manufacturing. Utilizing their proprietary suspension cell line, Pro10™, and the Aava™ manufacturing platform, Viralgen enables scalable and high-yield production for multiple AAV serotypes. Their state-of-the-art facilities in San Sebastián, Spain, are equipped with three cGMP-certified suites, each with a capacity of 2,000 liters, and are approved by AEMPS. Viralgen offers an extensive range of services, including plasmid production, process optimization, filling and finishing, as well as internal quality control testing. With over 2,000 batches of AAV produced, Viralgen provides efficient and reliable solutions that expedite the delivery of transformative gene therapies to patients. For more details, visit
viralgen.com and follow Viralgen on LinkedIn.